National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 61766-61767 [2017-28155]
Download as PDF
<![CDATA[
61766
Federal Register / Vol. 82, No. 249 / Friday, December 29, 2017 / Notices
under control number 0910–0014. The
information collection described in the
guidance for industry entitled ‘‘Formal
Meetings Between the FDA and
Sponsors or Applicants of PDUFA
Products’’ is approved by OMB under
control number 0910–0429. The
information collection described in the
guidance for industry entitled ‘‘Formal
Dispute Resolution: Sponsor Appeals
Above the Division Level’’ (available at
https://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatory
Information/Guidances/
UCM343101.pdf) is approved by OMB
under control number 0910–0430. The
information collection described in the
‘‘Evaluation of the Program for
Enhanced Review Transparency and
Communication for New Molecular
Entity New Drug Applications and
Original Biologics License Applications
in Prescription Drug User Fee Acts’’ is
approved by OMB under control
number 0910–0746. The information
collection described in the guidance for
industry entitled ‘‘Expedited Programs
for Serious Conditions—Drugs and
Biologics’’ (available at https://
www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatory
Information/Guidances/
UCM358301.pdf) is approved by OMB
under control number 0910–0765. The
information collection described in the
guidance for industry entitled ‘‘Formal
Meetings Between the FDA and
Biosimilar Biological Product Sponsors
or Applicants’’ (available at https://
www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatory
Information/Guidances/
UCM345649.pdf) is approved by OMB
under control number 0910–0802.
III. Electronic Access
ethrower on DSK3G9T082PROD with NOTICES
Persons with access to the internet
may obtain the guidance at https://
www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm, https://
www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatory
Information/default.htm, or https://
www.regulations.gov.
Dated: December 19, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–28139 Filed 12–28–17; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
20:09 Dec 28, 2017
Jkt 244001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on
Minority Health
Office of Minority Health,
Office of the Secretary, Department of
Health and Human Services.
ACTION: Notice of meeting.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that the Advisory Committee on
Minority Health (ACMH) will hold a
meeting. This meeting will be open to
the public. Preregistration is required
for both public attendance and
comment. Any individual who wishes
to attend the meetings and/or
participate in the public comment
session should email OMH-ACMH@
hhs.gov. Information about the meeting
is available from the designated contact
and will be posted on the website for
the Office of Minority Health (OMH),
www.minorityhealth.hhs.gov.
Information about ACMH activities can
be found on the OMH website under the
heading About OMH.
DATES: The meeting will be held on
Monday, March 26, 2018, from 9:00 a.m.
to 5:00 p.m. and Tuesday, March 27,
2018, from 9:00 a.m. to 1:00 p.m.
ADDRESSES: The meeting will be held at
the 5600 Fishers Lane Building, Room
05E29, 5600 Fishers Lane, Rockville,
Maryland 20857.
FOR FURTHER INFORMATION CONTACT: Dr.
Minh Wendt, Designated Federal
Officer, Advisory Committee on
Minority Health, Office of Minority
Health, Department of Health and
Human Services, Tower Building, 1101
Wootton Parkway, Suite 600, Rockville,
Maryland 20852. Phone: 240–453–8222;
fax: 240–453–8223; email OMH-ACMH@
hhs.gov.
SUPPLEMENTARY INFORMATION: In
accordance with Public Law 105–392,
the ACMH was established to provide
advice to the Deputy Assistant Secretary
for Minority Health on improving the
health of each racial and ethnic
minority group and on the development
of goals and specific program activities
of the OMH.
The topics to be discussed during this
meeting will include strategies to
improve the health of racial and ethnic
minority populations through the
development of health policies and
programs that will help eliminate health
disparities with an emphasis on serious
mental illness. The recommendations
will be given to the Deputy Assistant
Secretary for Minority Health.
SUMMARY:
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Public attendance at this meeting is
limited to space available. Individuals
who plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
designated contact person at least
fourteen (14) business days prior to the
meeting. Members of the public will
have an opportunity to provide
comments at the meeting. Public
comments will be limited to three
minutes per speaker. Individuals who
would like to submit written statements
should mail or fax their comments to
the Office of Minority Health at least
seven (7) business days prior to the
meeting. Any members of the public
who wish to have printed material
distributed to ACMH committee
members should submit their materials
to the Designated Federal Officer,
ACMH, Tower Building, 1101 Wootton
Parkway, Suite 600, Rockville,
Maryland 20852, prior to close of
business on Monday, March 19, 2018.
Dated: December 22, 2017.
Minh Wendt,
Designated Federal Officer, Advisory
Committee on Minority Health.
[FR Doc. 2017–28161 Filed 12–28–17; 8:45 am]
BILLING CODE 4150–29–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; AIDS Research Review
Committee (AIDSRRC) Independent SEP.
Date: January 18, 2018.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\29DEN1.SGM
29DEN1
Federal Register / Vol. 82, No. 249 / Friday, December 29, 2017 / Notices
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: JW Marriott New Orleans, 614 Canal
Street, New Orleans, LA 70130.
Contact Person: Birgit Neuhuber, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204,
MSC 9529, Bethesda, MD 20892–9529,
neuhuber@ninds.nih.gov.
Name of Committee: National Institutes of
Neurological Disorders and Stroke, Special
Emphasis Panel, NSD Member Conflict SEP.
Date: February 22, 2018.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: JW Marriott New Orleans, 614 Canal
Street, New Orleans, LA 70130.
Contact Person: Birgit Neuhuber, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Suite 3204,
MSC 9529, Bethesda, MD 20892–9529,
neuhuber@ninds.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: December 22, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: December 22, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–28155 Filed 12–28–17; 8:45 am]
[FR Doc. 2017–28157 Filed 12–28–17; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
ethrower on DSK3G9T082PROD with NOTICES
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Robert C. Unfer, Ph.D.,
Scientific Review Officer, Scientific Review
Program, DEA/NIAID/NIH/DHHS, 5601
Fishers Lane, Room 3F40 MSC 9823,
Rockville, MD 20892–9823, 240–669–5035,
unferrc@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; PHS 2018–1 Topic 54 & 55:
Adjuvant Discovery & Development for
Autoimmune Diseases.
Date: January 31, 2018.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Dharmendar Rathore,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, Room 3G30, National Institutes of
Health/NIAID, 5601 Fishers Lane, Drive,
MSC 9823, Bethesda, MD 20892–9823, 240–
669–5058, rathored@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke, Initial
Review Group, Neurological Sciences and
Disorders B.
Date: February 22, 2018.
VerDate Sep<11>2014
20:09 Dec 28, 2017
Jkt 244001
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Initial Review Group; Behavior and
Social Science of Aging Review Committee
NIA–S.
Date: February 1–2, 2018.
Time: 10:00 a.m. to 3:00 p.m.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
61767
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Kimberly Firth, Ph.D.,
National Institute on Aging, Gateway
Building, 7201 Wisconsin Avenue, Suite
2C212, Bethesda, MD 20892, 301–402–7702,
kimberly.firth@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: December 26, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–28154 Filed 12–28–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; PHS 2018–1 Topic 55:
Adjuvant Development for Viral Diseases
Vaccines.
Date: January 26, 2018.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Dharmendar Rathore,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, Room 3G30, National Institutes of
Health/NIAID, 5601 Fishers Lane, Drive,
MSC 9823, Bethesda, MD 20892–9823, 240–
669–5058, rathored@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
E:\FR\FM\29DEN1.SGM
29DEN1
]]>Agencies
[Federal Register Volume 82, Number 249 (Friday, December 29, 2017)]
[Notices]
[Pages 61766-61767]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-28155]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; AIDS Research Review Committee
(AIDSRRC) Independent SEP.
Date: January 18, 2018.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
[[Page 61767]]
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Robert C. Unfer, Ph.D., Scientific Review
Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers
Lane, Room 3F40 MSC 9823, Rockville, MD 20892-9823, 240-669-5035,
[email protected].
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; PHS 2018-1 Topic 54 & 55: Adjuvant
Discovery & Development for Autoimmune Diseases.
Date: January 31, 2018.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Dharmendar Rathore, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, Room 3G30, National Institutes of Health/NIAID, 5601
Fishers Lane, Drive, MSC 9823, Bethesda, MD 20892-9823, 240-669-
5058, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: December 22, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-28155 Filed 12-28-17; 8:45 am]
BILLING CODE 4140-01-P
